Everhope Oncology Launches First Cancer Daycare Centre in Gurugram — Revolutionizing Cancer Care with Compassion, Precision and Convenience
Everhope Oncology takes the anxiety out of cancer treatment — with zero…
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA
AHMEDABAD, India, Aug. 6, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its…
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information…
Aicuris Presents Pharmacokinetic Data from the First-in-Human Clinical Trial of AIC468, a Novel Antisense Oligonucleotide Targeting BK Virus, at World Transplant Congress
Initial results from the First in Human (FIH) Phase 1 trial evaluating…
Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress
PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co.,…
FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria,…
Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in…
vVARDIS Drill-Free Solution Curodont Has Treated Over One Million Teeth in 18 Months and Is the Fastest Growing Dental Care Product in Its Category
Clinical adoption of Curodont™ is helping to elevate the standard of care…
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimers disease
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test…
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+
July 22, 2025 02:00 ET Â | Source: Scancell Holdings Plc SCOPE trial…